{
    "nct_id": "NCT03118492",
    "official_title": "A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis",
    "inclusion_criteria": "* Diagnosis of primary of secondary myelofibrosis with transplant indication by Dynamic International Prognostic Scoring System (DIPSS)-plus (> intermediate-1)\n* Patients >= age 50 must have a comorbidity score (hematopoietic cell transplant-comorbidity index [HCT-CI]) < 4 (Sorror)\n* Patients can be in chronic phase (CP) with bone marrow (BM) blast count =< 15% as long as no evidence of disease acceleration per principal investigator (PI) and treating physician's opinion or after progression to acute myeloid leukemia (AML) and achieved =< 5% BM blasts (morphologic complete remission [CR] prior to transplant)\n* Lack of an human leukocyte antigen (HLA) matched donor or need to proceed fast to transplantation when a patient does not have an immediately available matched unrelated donor (typed by high-resolution in the registry)\n* Performance status >= 70% (Karnofsky); patients > 50 years should have adequate cognitive function; any concerns regarding cognitive function should be addressed by a geriatrician/neurologist\n* Alanine aminotransferase (ALT)/aspartate aminotransferase (AST)/bilirubin =< 5 X upper limit of normal (ULN)\n* Measured creatinine clearance > 60 mls/min\n* Left ventricular ejection fraction (LVEF) >= 50%\n* Corrected carbon monoxide diffusing capability (DLCOc) >= 50%\n* No active infections\n* Prior treatment with JAK2 inhibitor therapy is not excluded; a JAK2 inhibitor will need to be stopped 1-2 days prior to starting conditioning regimen\n* DONOR: Documented informed consent per local, state and federal guidelines\n* DONOR: Genotypically haploidentical as determined by HLA typing\n\n  * Preferably a non-maternal HLA haploidentical relative due to data of high incidence of graft failure with use of maternal HLA haploidentical cells\n  * Eligible donors include biological parents, siblings or half-siblings, children, or cousins in rare instances\n* DONOR: Absence of pre-existing donor-specific anti-HLA antibodies (DSA) in the recipient; Patients with pre-existing DSA could undergo desensitization per City of Hope (COH) standard operating procedures [SOP] and should have DSA < MFI of 2000 prior to conditioning at discretion of PI\n* DONOR: Infectious disease screening performed within 30 days prior to stem cell mobilization per federal guidelines and is:\n\n  * Seronegative for HIV 1+2 antibody (Ab) and/or HIV polymerase chain reaction (PCR), human T-cell leukemia virus (HTLV) I/II Ab, hepatitis B virus surface antigen (HBsAg), hepatitis B virus surface antibody (HBcAb), hepatitis C virus (HCV) Ab\n  * Negative rapid plasma reagin (RPR) for syphilis\n* DONOR: Women of childbearing potential (WOCBP): Urine pregnancy testing performed within 7 days prior to stem cell mobilization\n* DONOR: Is approved and completed evaluation prior to recipient initiation of the preparative regimen per institutional guidelines\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Evidence of severe portal hypertension with evidence of decompensation either with bleeding varices, large volume ascites, or hepatic encephalopathy\n* In a bone marrow biopsy 4 weeks prior to start of conditioning on study:\n\n  * > 15% bone marrow blasts at transplant if no history of AML and per PI and treating physician's opinion of disease acceleration\n  * > 5% if had previous progression to AML\n* Human immunodeficiency virus (HIV) positive; active hepatitis B or C\n* Patients with active infections; the PI is the final arbiter of the eligibility\n* Patients with evidence of severe pulmonary hypertension by echocardiogram and confirmed by a subsequent right side cardiac catheterization pre-enrollment\n* Liver cirrhosis\n* Prior central nervous system (CNS) involvement by tumor cells\n* History of another primary malignancy that has not been in remission for at least 3 years (the following are exempt from the 3-year limit: non-melanoma skin cancer, fully excised melanoma in situ [stage 0], curatively treated localized prostate cancer, and cervical or breast carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear)\n* Positive beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization\n* Noncompliance - inability or unwillingness to comply with medical recommendations regarding therapy or follow-up, including smoking tobacco\n* DONOR: Has undergone solid organ, stem cell, bone marrow or blood transplantation\n* DONOR: Receiving any investigational agents, or concurrent biological, chemotherapy, immunosuppression or radiation therapy\n* DONOR: Active infection\n* DONOR: Thrombocytopenia < 150,000 cells /mm^3 at baseline evaluation\n* DONOR: Sero-positive for HIV-1 & 2 antibody, HTLV-I & II antibody, hepatitis B virus (HBV) and HCV\n* DONOR: Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis\n* DONOR: Factors which place the donor at increased risk for complications from leukapheresis or G-CSF therapy\n* DONOR: WOCBP: Pregnant or =< 6 months breastfeeding",
    "miscellaneous_criteria": ""
}